Jump to Content
User Account
  • Sign In to save searches and organize your favorite content.
  • Not registered? Sign up
  • My Content (0)

    Recently viewed (0)

    • Save Entry
  • Searches (0)

    Recently viewed (0)

    • Save Search
More
  • Subscriptions
  • Join E-mail List
  • Help
JNCCN
Menu
  • Home
  • Content
    • Current Issue
    • Past Issues
    • Featured Online Content
    • Supplements
    • NCCN Meeting Highlights
    • JNCCN In the News
    • NCCN News
    • Highlights of the NCCN Oncology Research Program
    • Video Roundtables
  • CE
  • JNCCN 360
  • Author Center
    • Call for Papers
    • Submit a Manuscript
    • Information for Authors
    • Reprints/Permissions
  • About
    • JNCCN
    • Editorial Board
    • Editorial Calendar
    • NCCN
    • Conexiant (FKA Harborside)
  • Reducing Disparities in Cancer Care
Search
Close
Advanced Search Help
  • toggle Targeted Treatment Considerations in EGFR-Mutated NSCLC
    • Case 1
    • Case 2
    • Case 3
  • toggle Targeted Therapies for HER2-Positive Breast Cancer
    • Case 1
    • Case 2
    • Case 3
  • toggle Management of Ovarian Function in Premenopausal and Perimenopausal Patients With Early or Advanced Breast Cancer
    • Case 1
    • Case 2
    • Case 3
  • toggle Tailoring Targeted Therapies for Treatment of BRAF-Mutated Metastatic Colorectal Cancer
    • Case 1
    • Case 2
    • Case 3
    • Case 4
  • toggle Clinical Conversations in Hormone Receptor–Positive, HER2-Negative Breast Cancer
    • Case 1
    • Case 2
    • Case 3
    • Case 4
    • Case 5
  • Home
  • Content
  • Video Roundtables
  • Print
  • Email this link

    Share Link


    Copy this link, or click below to email it to a friend
    Email this link
    or copy the link directly:
    The link was not copied. Your current browser may not support copying via this button.
    Link copied successfully

Video Roundtables

Targeted Treatment Considerations in EGFR-Mutated NSCLC

Targeted Therapies for HER2-Positive Breast Cancer

Management of Ovarian Function in Premenopausal and Perimenopausal Patients With Early or Advanced Breast Cancer

Tailoring Targeted Therapies for Treatment of BRAF-Mutated Metastatic Colorectal Cancer

Clinical Conversations in Hormone Receptor–Positive, HER2-Negative Breast Cancer

  • Advertising
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Permissions
  • Disclaimer

© 2019-2024 National Comprehensive Cancer Network

Follow us on: Share Share Share

Powered by:

PubFactory
  • [18.97.14.90]
  • 18.97.14.90